PMID- 26205460
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20170206
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 96
IP  - 6
DP  - 2016 Jun
TI  - Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation 
      and response to therapy.
PG  - 593-601
LID - 10.1111/ejh.12638 [doi]
AB  - Patients with essential thrombocythemia (ET) often suffer from neurological 
      symptoms (NS) not ever resulting from previous thrombotic cerebral events (TCE). 
      We reported NS occurred in 282 patients, in order to identify the factors 
      influencing ET-related NS in the absence of TCE, and the response to therapy. 
      Overall, 116 of 282 patients (41%) presented NS; 101 of them (87%) reported 
      subjective transient and fluctuating NS, without concurrent TCE, which we defined 
      as ET-related NS, by frequency: cephalalgia, chronic paresthesias, dizziness or 
      hypotension, visual disturbances, and tinnitus. In univariate analysis, 
      ET-related NS resulted more frequently in young people (P = 0.017) and in females 
      (P = 0.025). We found a higher prevalence of JAK2V617F mutation in ET-related NS 
      patients (P = 0.021). In multivariate analysis, gender (P = 0.024) and JAK2V617F 
      mutation (P = 0.041) remained significantly associated with the development of 
      ET-related NS, with a risk of about four times higher for JAK2V617F-mutated 
      patients (OR = 3.75). Ninety-seven of 101 patients with ET-related NS received an 
      antiplatelet (AP) agent at the time of NS, whereas only selected high-risk 
      ET-related NS patients were treated with a cytoreductive drug, according to the 
      published guidelines and similarly to patients without NS. We observed that only 
      32 of 97 (33%) patients with ET-related NS achieved a complete response after AP 
      treatment. Among the 65 non-responder patients, 36 (55.4%) improved NS after the 
      introduction of cytoreductive therapy; therefore, the addition of cytoreductive 
      treatment should be considered in this setting.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Aroldi, Andrea
AU  - Aroldi A
AD  - Hematology Division, San Gerardo Hospital, University of Milano-Bicocca, Monza, 
      Italy.
FAU - Cecchetti, Caterina
AU  - Cecchetti C
AD  - Hematology Division, San Gerardo Hospital, University of Milano-Bicocca, Monza, 
      Italy.
FAU - Colombo, Arianna
AU  - Colombo A
AD  - Centro Ricerca Tettamanti, San Gerardo Hospital, University of Milano-Bicocca, 
      Monza, Italy.
FAU - Cattaneo, Leonardo
AU  - Cattaneo L
AD  - Hematology Division, San Gerardo Hospital, University of Milano-Bicocca, Monza, 
      Italy.
FAU - Pioltelli, Pietro Enrico
AU  - Pioltelli PE
AD  - Hematology Division, San Gerardo Hospital, University of Milano-Bicocca, Monza, 
      Italy.
FAU - Pogliani, Enrico Maria
AU  - Pogliani EM
AD  - Dipartimento di Scienze della Salute, University of Milano-Bicocca, Monza, Italy.
FAU - Elli, Elena Maria
AU  - Elli EM
AD  - Hematology Division, San Gerardo Hospital, University of Milano-Bicocca, Monza, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20150820
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Codon)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 2.7.10.2 (Janus Kinase 2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Codon
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Janus Kinase 2/genetics
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Nervous System Diseases/*diagnosis/*etiology
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prognosis
MH  - Risk Factors
MH  - Thrombocythemia, Essential/*complications/drug therapy/genetics/mortality
MH  - Treatment Outcome
OTO - NOTNLM
OT  - JAK2V617F mutation
OT  - essential thrombocythemia
OT  - myeloproliferative neoplasm
OT  - neurological symptoms
OT  - platelets
EDAT- 2015/07/25 06:00
MHDA- 2017/02/07 06:00
CRDT- 2015/07/25 06:00
PHST- 2015/07/19 00:00 [accepted]
PHST- 2015/07/25 06:00 [entrez]
PHST- 2015/07/25 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
AID - 10.1111/ejh.12638 [doi]
PST - ppublish
SO  - Eur J Haematol. 2016 Jun;96(6):593-601. doi: 10.1111/ejh.12638. Epub 2015 Aug 20.